公开(公告)号：US10816541B2

公开(公告)日：2020-10-27

申请号：US15542263

申请日：2016-02-26

Applicant: AMOREPACIFIC CORPORATION

Inventor： Chang Seok Lee ,  Heung Soo Baek ,  Yung Hyup Joo ,  Jeong Hwan Kim ,  Hong-Ju Shin ,  Mi Young Park ,  Song Seok Shin

IPC: G01N33/50

Abstract: In one aspect of the present specification, provided is a method for predicting a side effect of a whitening ingredient, the method comprising measuring at least one of i) the increase in toxicity according to long-term use of a whitening ingredient, ii) the difference between a concentration having whitening effect and a concentration having cell toxicity, and iii) the increase in sensitivity to the whitening ingredient according to ultraviolet pretreatment. In addition, the method has an effect of effectively predicting whether a side effect will occur if the whitening ingredient is used for a long time.

公开(公告)号：US11957669B2

公开(公告)日：2024-04-16

申请号：US16638038

申请日：2018-08-10

Applicant: AMOREPACIFIC CORPORATION

Inventor： Joon Ho Choi ,  Won Kyung Cho ,  Kwang-Hyun Shin ,  Byoung Young Woo ,  Ki-Wha Lee ,  Min-Soo Kim ,  Jong Hwa Roh ,  Mi Young Park ,  Young-Ho Park ,  Eun Sil Park ,  Jae Hong Park

IPC: A61K31/44 ,  A61K9/00 ,  A61K47/38

CPC classification number: A61K31/44 ,  A61K9/0014 ,  A61K47/38

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.